Including Anti-PD-1 in First-Line Ups Survival in Biliary Tract Cancer Another option for difficult-to-treat disease Apr 17, 2023
'Potential' New Option for Operable NSCLC Adding perioperative durvalumab to neoadjuvant chemo improved pCR rates, event-free survival Apr 17, 2023
Adjuvant Combo May Change Practice in High-Risk Liver Cancer Atezolizumab-bevacizumab reduced the risk of recurrence by about 30% Apr 17, 2023
Personalized Cancer Vaccine Boosts Recurrence-Free Survival in Melanoma Clinical implications apply to virtually all solid tumors and possibly hematologic malignancies Apr 17, 2023
Taxane, Anthracycline Combo Most Effective in Reducing Breast Cancer Recurrence Chemotherapy regimens with higher cumulative dose provide greatest benefit Apr 14, 2023
Oral Drug Improves Sunlight Tolerance in Genetic Photosensitivity Disorders Dersimelagon significantly extended time to sun-related prodromal symptoms Apr 12, 2023
Blood Donor's Sex Makes No Difference for Survival Only difference seen was higher incidence of MRSA infection in recipients of female donor blood Apr 12, 2023
Older Men Still Overscreened for Prostate Cancer, Survey Says PSA screening rates over 50% for men 70 and up, despite USPSTF recommendations against it Apr 11, 2023
SYK Inhibitor Promising in Early Trial of Primary ITP Sovleplenib demonstrated "consistent response" as second-line treatment Apr 11, 2023
Local Anesthesia Before Breast Cancer Surgery Improves OS in Randomized Trial Intervention is inexpensive, easy to implement, researchers say Apr 07, 2023
Leading Causes of Death Hit Childhood Cancer Survivors Earlier But excess risk lowest in survivors with a healthy lifestyle Apr 06, 2023
CAR T-Cell Therapy Feasible, Safe in Advanced Neuroblastoma ORR of 63% with GD2-targeting product in kids with relapsed, refractory high-risk disease Apr 06, 2023
Major Survival Gain With Immunotherapy in Lymphomatoid Granulomatosis Median overall survival reached 20 years with interferon alfa-2b in low-grade disease Apr 05, 2023
Does Your 80-Year-Old Patient Really Need That Colonoscopy? Physicians often ignore life expectancy in screening decisions, study finds Apr 04, 2023
FDA Greenlights New First-Line Regimen in Bladder Cancer Enfortumab vedotin plus pembrolizumab approved for cisplatin-ineligible patients Apr 04, 2023
Post-Immunotherapy Combo Promising in Advanced RCC Duration of response reaches 18.6 months with belzutifan plus cabozantinib Apr 03, 2023
VTE Risk in Recurrent Ovarian Cancer Increases With More Lines of Chemotherapy Prospective study in heavily treated population is warranted, researcher says Mar 30, 2023
Obesity's Impact on Uterine Cancer Risk Greater in Younger Age Groups Overall risk and risk of endometrioid subtype 20- to 30-fold greater in women younger than 35 Mar 30, 2023
A 'Double Whammy' for Gastric Cancer Risk H. pylori infection and certain pathogenic variants linked with large excess risk Mar 29, 2023
Phase III Trials 'Hit a Home Run' in Advanced Endometrial Cancer Adding immunotherapy will change frontline treatment, experts say Mar 28, 2023
Novel Strategies Show Winning Potential in Ovarian Cancer High response rates in small studies of immuno-oncology combination, neoadjuvant olaparib Mar 28, 2023
High Out-of-Pocket Costs Tied to Less Follow-Up After Initial Mammography Plans dominated by copays and deductibles are associated with higher out-of-pocket costs Mar 27, 2023
No Survival Benefit With CRT Versus Chemo for Locally Advanced Endometrial Cancer Long-running clinical trial failed to identify any subgroup that fared better with CRT Mar 27, 2023
FDA Greenlights First Drug for Rare Immunodeficiency Disease Activated PI3K-delta syndrome may have a new standard of care Mar 27, 2023
Make the Diagnosis: This Bump on His Nose is a Tricky Diagnosis A 52-year-old man visited his doctor for a new growth on his nose. Can you diagnosis the patient? Mar 27, 2023
CRT Regimen Boosts Complete Response Rate in Unresectable Vulvar Cancer Pathologic response rises to 73% versus 50% in historical control group Mar 27, 2023
CDK4/6 Inhibition Active in Recurrent Low-Grade Serous Ovarian Cancer Responses in a fourth of patients, clinical benefit in up to 90% Mar 26, 2023
Sam Neill's Rare Lymphoma The actor noticed swollen glands while on tour for "Jurassic World Dominion" Mar 23, 2023
Progestin-Only Birth Control Linked to Small Increase in Breast Cancer Risk But risk is similar to combined hormonal contraceptive use Mar 22, 2023
FDA OKs Another PD-1 Inhibitor for Merkel Cell Carcinoma Retifanlimab produced responses in 52% of patients with untreated unresectable disease Mar 22, 2023
Cancer Transmission From Organ Donors With Brain Tumors Not Much of a Risk In U.K. cohort study, no cases of transmission observed Mar 22, 2023
Sickle Cell Disease Patients Miss Out on Decades of Life What effects might emerging therapies have on real-world survival? Mar 17, 2023
FDA Allows Lower Risk Designation for Snuff Product The brand joins a limited few granted modified risk tobacco claims Mar 16, 2023
Laparoscopy, Surgery in a Draw for Gastric Cancer Survival Laparoscopy-assisted distal gastrectomy noninferior for both relapse-free, overall survival Mar 15, 2023
Take Risk Into Account Before Repeat Surveillance Colonoscopy, Study Says 58% of seniors with limited life expectancy, no significant findings invited for another round Mar 14, 2023
Novel PET Imaging Agent Accurately IDs Clear Cell Renal Cancers ZIRCON trial meets sensitivity and specificity targets Mar 13, 2023
FDA Panel Endorses New First-Line Lymphoma Regimen POLARIX trial supports a favorable risk-benefit profile for polatuzumab vedotin, ODAC members say Mar 10, 2023
Focus on Optimizing Use of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer Choice of agent, post-progression treatment, and resistance mechanisms top unanswered questions Mar 08, 2023
Understanding of HER2-Low Breast Cancer Continues to Evolve New breast cancer subtype proves challenging to define molecularly, pathologically, clinically Mar 07, 2023
FDA Not Quite Sold on Polivy in Frontline Large B-Cell Lymphoma Regimen Ahead of ODAC meeting, agency reviewers suggest modest PFS results in POLARIX "raise uncertainty" Mar 07, 2023
